Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and the average volume of the stock remained 934.20 million shares. The beta of the stock remained 1.42. Neuralstem, Inc. (NYSEMKT:CUR) insider ownership is 2.20%.

OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) rose 6.77 percent to $4.26 yesterday on volume of 3.87 million shares. The intra-day range of the stock was $4.00 to $4.44. OXiGENE Inc (NASDAQ:OXGN) has a market capitalization of $48.86 million.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s stock on Mar17, 2014 reported a increase of 6.32% to the closing price of $6.06. Its fifty two weeks range is $0.43 -$6.75. The total market capitalization recorded $449.16 million. The overall volume in the last trading session was 3,064,224 million shares. In its share capital, Idera Pharmaceuticals Inc (NASDAQ:IDRA) has 45.72 million outstanding shares.

Shares of Five Prime Therapeutics (NASDAQ:FPRX) , a clinical-stage biopharmaceutical company focused on developing protein therapeutics to fight cancer and other inflammatory diseases, jumped as much as 22% after announcing a collaborative deal with Bristol-Myers Squibb (NYSE: BMY ) before the opening bell. On Monday, shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) advanced 22.61% to close the day at $22.99. Company return on investment (ROI) is 24.00% and its monthly performance is recorded as 35.31%. Five Prime Therapeutics Inc (NASDAQ:FPRX) quarterly revenue growth is 38.41%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone